Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Revolution Medicines Inc (RVMD)

Revolution Medicines Inc (RVMD)
32.60 x 1 37.15 x 1
Post-market by (Cboe BZX)
35.72 +2.05 (+6.09%) 04/11/25 [NASDAQ]
32.60 x 1 37.15 x 1
Post-market 35.72 unch (unch) 16:20 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
33.25
Day High
35.89
Open 33.74
Previous Close 33.67 33.67
Volume 1,815,400 1,815,400
Avg Vol 1,916,775 1,916,775
Stochastic %K 55.20% 55.20%
Weighted Alpha -13.73 -13.73
5-Day Change +4.40 (+14.05%) +4.40 (+14.05%)
52-Week Range 29.17 - 62.40 29.17 - 62.40
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,640,813
  • Shares Outstanding, K 185,913
  • Annual Sales, $ 0 K
  • Annual Income, $ -600,090 K
  • EBIT $ -690 M
  • EBITDA $ -722 M
  • 60-Month Beta 1.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.50

Options Overview Details

View History
  • Implied Volatility 70.90% ( -2.31%)
  • Historical Volatility 62.68%
  • IV Percentile 75%
  • IV Rank 28.12%
  • IV High 147.63% on 07/11/24
  • IV Low 40.89% on 01/14/25
  • Put/Call Vol Ratio 0.08
  • Today's Volume 26
  • Volume Avg (30-Day) 265
  • Put/Call OI Ratio 1.47
  • Today's Open Interest 14,842
  • Open Int (30-Day) 13,974

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.10
  • Number of Estimates 7
  • High Estimate -0.89
  • Low Estimate -1.23
  • Prior Year -0.70
  • Growth Rate Est. (year over year) -57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.17 +22.45%
on 04/07/25
Period Open: 38.89
40.87 -12.60%
on 03/12/25
-3.17 (-8.15%)
since 03/11/25
3-Month
29.17 +22.45%
on 04/07/25
Period Open: 41.78
44.68 -20.05%
on 02/05/25
-6.06 (-14.50%)
since 01/10/25
52-Week
29.17 +22.45%
on 04/07/25
Period Open: 37.41
62.40 -42.76%
on 11/11/24
-1.69 (-4.52%)
since 04/11/24

Most Recent Stories

More News
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

RVMD : 35.72 (+6.09%)
Revolution Medicines to Participate in April 2025 Investor Conferences

RVMD : 35.72 (+6.09%)
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

RVMD : 35.72 (+6.09%)
Revolution Medicines to Participate in March 2025 Investor Conferences

RVMD : 35.72 (+6.09%)
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

RVMD : 35.72 (+6.09%)
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

RVMD : 35.72 (+6.09%)
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

RVMD : 35.72 (+6.09%)
Revolution Medicines Closes $862.5 Million Underwritten Public Offering of Common Stock

Revolution Medicines closed a public offering of 16.6 million shares, raising $862.5 million for RAS-addicted cancer therapies.Quiver AI SummaryRevolution Medicines, Inc. has successfully completed its...

RVMD : 35.72 (+6.09%)
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

RVMD : 35.72 (+6.09%)
Revolution Medicines Prices Public Offering of Common Stock and Pre-Funded Warrants, Aiming for $750 Million in Proceeds

Revolution Medicines announced a public offering of 14.1 million shares priced at $46 each, aiming for $750 million proceeds.Quiver AI SummaryRevolution Medicines, Inc., a clinical-stage oncology company...

RVMD : 35.72 (+6.09%)
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

RVMD : 35.72 (+6.09%)
Revolution Medicines, Inc. Provides Promising Clinical Updates on RMC-6236 for RAS-Addicted Cancers

Revolution Medicines provides updates on RMC-6236 and RMC-6291 in clinical trials for RAS-addicted cancers.Quiver AI SummaryRevolution Medicines, Inc. provided a clinical update on its RAS(ON) inhibitor...

RVMD : 35.72 (+6.09%)
Revolution Medicines Announces Commencement of Public Offering of Common Stock

RVMD : 35.72 (+6.09%)
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

RVMD : 35.72 (+6.09%)
Revolution Medicines to Host Investor Webcast on RAS(ON) Inhibitor Clinical Updates

Revolution Medicines will host an investor webcast on December 2, 2024, to discuss updates on its RAS(ON) inhibitor portfolio.Quiver AI SummaryRevolution Medicines, Inc., a clinical-stage oncology company...

RVMD : 35.72 (+6.09%)
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

RVMD : 35.72 (+6.09%)
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

RVMD : 35.72 (+6.09%)
Revolution Medicines to Participate in Upcoming Investor Conferences

RVMD : 35.72 (+6.09%)
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

RVMD : 35.72 (+6.09%)
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

RVMD : 35.72 (+6.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways. Revolution Medicines Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 39.30
2nd Resistance Point 37.59
1st Resistance Point 36.66
Last Price 35.72
1st Support Level 34.02
2nd Support Level 32.31
3rd Support Level 31.38

See More

52-Week High 62.40
Fibonacci 61.8% 49.71
Fibonacci 50% 45.78
Fibonacci 38.2% 41.86
Last Price 35.72
52-Week Low 29.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.